# Point72

> Point72 is a VC fund in Stamford backing Biotechnology and Pharmaceutical. See 40 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Stamford, United States
- Total investments: 40
- Last investment: Apr 2026
- Lead investor: 20%
- Fund size: $600M
- Last fund: Nov 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/point72-asset-management-l-p-
- X (Twitter): https://twitter.com/point72asset
- Website: https://www.point72.com

Point72 is a VC fund in Stamford focused on Biotechnology and Pharmaceutical. Point72 invests in multiple asset classes and strategies worldwide.

## Contacts

5 contacts available for Point72. Shizune tracks 9 team members at Point72. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/point72?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 33% |
| Pharmaceutical | 6 | 15% |
| Therapeutics | 5 | 13% |
| Health Care | 4 | 10% |
| FinTech | 3 | 8% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 5 | 13% |
| Series B | 4 | 10% |
| Series C | 4 | 10% |
| Series A | 2 | 5% |
| Seed | 1 | 3% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 16 | 40% |
| Canada | 1 | 3% |
| Israel | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anup Chamrajnagar | Ventures Investor | 0 | — |
| Philip Farese | Senior Researcher | 0 | — |
| Steven Cohen | Chairman, Chief Executive Officer, and Co-Chief Investment Officer | 13 | — |
| Deirdre Alphenaar | Head of Market Intelligence Integration | 0 | — |
| Joel Barron | Head of Product Design | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SiFive | SiFive designs chips for the semiconductor industry. It offers the system on a chip for the microcontroller, embedded, IoT, and wearable applications; and toolset to provide debug capabilities. SiFive brings the power of open source and software automation to the semiconductor industry, making it possible to develop new hardware faster and moreaffordably than ever before. With our platform for rapidly designing, testing, and building RISC‑V-based core IP and chips, we’re accelerating the pace of innovation for businesses large and small. | $400M | Series G | Apr 09, 2026 |  |
| Rivet Industries | Rivet Industries delivers front line hardware and software to the world's most important workers. | $57.5M | Series A | Mar 31, 2026 |  |
| Ovid Therapeutics | Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M | Post-IPO Equity | Mar 17, 2026 |  |
| Nscale | Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $2B | Series C | Mar 09, 2026 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $140M | Post-IPO Equity | Feb 03, 2026 |  |
| TONIX PHARMACEUTICALS HOLDING CORP. | Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring, and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of the central nervous system (CNS) and immunology product candidates. The CNS portfolio includes bothsmall molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. | $20M | Post-IPO Equity | Dec 29, 2025 |  |
| X-energy | X-Energy is a nuclear reactor and fuel design engineering company that develops Generation IV, high-temperature gas-cooled small modular reactors (SMRs) together with proprietary TRISO-X particle fuel. Their flagship reactor, the Xe-100, delivers about 80 MWe per unit and can be scaled in modular “packs” to reach higher output. X-Energy also buildsits own TRISO-X fuel to maintain supply control and quality. In addition, the company operates a plant support center to provide fleet monitoring, maintenance planning, training, and diagnostics for its reactor customers. | $700M | Series D | Nov 24, 2025 |  |
| Cybin | Cybin is a biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin's mission is to revolutionize mental healthcare. | $175M | Post-IPO Equity | Oct 28, 2025 |  |
| Nscale | Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $433M | Series C | Oct 01, 2025 |  |
| Nscale | Nscale is an AI GPU cloud platform that provides scale computing to the generative AI market. It develops AI-ready data centers, deploys GPU infrastructure, and delivers AI cloud services. Its AI private cloud platform supports the entire generative AI lifecycle, enabling developers to run and train AI models. It also provides bare metal andvirtualized GPU nodes, Kubernetes-native services (NKS), AI workload scheduling empowered by SLURM, and advanced serverless and dedicated inferencing options. | $1.1B | Series B | Sep 25, 2025 |  |

10 of 40 investments shown.

## Co-investors
- Eventide — VC Fund, 6 deals together
- Fidelity — VC Fund, 6 deals together
- Cowen Healthcare Investments — VC Fund, 5 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 4 deals together
- [NVIDIA](https://shizune.co/investors/profile/nvidia) — VC Fund, 4 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Point72 invest in?

Point72 invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Point72?

Public channels for Point72 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Point72?

The team at Point72 includes Anup Chamrajnagar (Ventures Investor), Philip Farese (Senior Researcher) and Steven Cohen (Chairman, Chief Executive Officer, and Co-Chief Investment Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co